KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLoans and Notes ReceivablesLong-Term Debt IssuancesNon-Current ReceivablesReceivables RefundsShares OutstandingShares Repurchased
Ratios

Royalty Pharma (RPRX) Long-Term Debt Issuances: 2020-2025

  • Royalty Pharma's Long-Term Debt Issuances was N/A to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 billion, marking a year-over-year change of. This contributed to the annual value of $1.5 billion for FY2024, which is 320.35% up from last year.
  • Per Royalty Pharma's latest filing, its Long-Term Debt Issuances stood at $2.0 billion for Q3 2025, which was up 458.42% from $350.0 million recorded in Q4 2023.
  • Royalty Pharma's Long-Term Debt Issuances' 5-year high stood at $2.0 billion during Q3 2025, with a 5-year trough of $350.0 million in Q4 2023.
  • Over the past 2 years, Royalty Pharma's median Long-Term Debt Issuances value was $1.2 billion (recorded in 2023), while the average stood at $1.2 billion.
  • Data for Royalty Pharma's Long-Term Debt Issuances shows a maximum YoY crashed of 78.25% (in 2021) over the last 5 years.
  • Over the past 3 years, Royalty Pharma's Long-Term Debt Issuances (Quarterly) stood at $1.3 billion in 2021, then followed by $350.0 million in 2023, then followed by $2.0 billion in 2025.
  • Its Long-Term Debt Issuances was $2.0 billion in Q3 2025, compared to $350.0 million in Q4 2023 and $1.3 billion in Q3 2021.